Search

Displaying results 8221 - 8230 of 10000 in total
  1. Drug

    ACT-451840

    go.drugbank.com/drugs/DB13054
    Investigational

    ACT-451840 has been used in trials studying Malaria.

  2. Drug

    IK-930

    go.drugbank.com/drugs/DB18149
    Investigational

    IK-930 is an oral, paralog-selective TEAD inhibitor.

  3. Drug

    Chlorophetanol

    go.drugbank.com/drugs/DB11368
    Experimental

    Chlorophetanol is an agent known to have antifungal activities.

  4. Drug

    Ceftiofur

    go.drugbank.com/drugs/DB11485
    ExperimentalVet approved

    E. coli strains resistant to ceftiofur have been reported. … Ceftiofur is a third generation cephalosporin antibiotic, first described in 1987, and now used in veterinary medicine.

  5. Drug

    VH3739937

    go.drugbank.com/drugs/DB25287
    Investigational

    VH3739937 is under investigation in clinical trial NCT06533280 (VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect

  6. Drug

    Tanogitran

    go.drugbank.com/drugs/DB21367
    Investigational

    Tanogitran is under investigation in clinical trial NCT02254057 (Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects).

  7. Drug

    Rosabulin

    go.drugbank.com/drugs/DB20161
    Investigational

    Rosabulin is under investigation in clinical trial NCT00276913 (A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors).

  8. Drug

    Freneslerbart

    go.drugbank.com/drugs/DB19080
    Investigational

    Freneslerbart is under investigation in clinical trial NCT04981717 (A Study to Examine the Efficacy and Safety of Anti-fel D 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic

  9. Drug

    Crelosidenib

    go.drugbank.com/drugs/DB21642
    Investigational

    Crelosidenib is under investigation in clinical trial NCT04603001 (Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations).

  10. Drug

    QRX-411

    go.drugbank.com/drugs/DB17868
    Experimental

    It addresses the underlying cause of Usher syndrome due to the c.7595-2144A>G mutation in the _USH2A_ gene.[L46777] … QRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading to the production of the functional USH2A protein.